These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1435 related items for PubMed ID: 25599322

  • 1. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, Clark JW, Faris JE, Goyal L, Kwak EL, Murphy JE, Ting DT, Wo JY, Zhu AX, Warshaw AL, Lillemoe KD, Fernández-del Castillo C.
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [Abstract] [Full Text] [Related]

  • 2. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O, Bachet JB.
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [Abstract] [Full Text] [Related]

  • 3. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G, Todaro V, Boninsegna E, Negrelli R, Sureka B, Bonamini D, Salvia R, Manfredi R, Pozzi Mucelli R, Bassi C.
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [Abstract] [Full Text] [Related]

  • 4. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, Deshpande V, Wo JY, Ryan DP, Allen JN, Blaszkowsky LS, Clark JW, Murphy JE, Nipp RD, Parikh A, Qadan M, Warshaw AL, Hong TS, Lillemoe KD, Ferrone CR.
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [Abstract] [Full Text] [Related]

  • 5. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM.
    BMC Cancer; 2012 May 29; 12():199. PubMed ID: 22642850
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
    Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B.
    Oncologist; 2014 Mar 29; 19(3):266-74. PubMed ID: 24569947
    [Abstract] [Full Text] [Related]

  • 7. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
    Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T.
    Ann Surg Oncol; 2015 Apr 29; 22(4):1153-9. PubMed ID: 25358667
    [Abstract] [Full Text] [Related]

  • 8. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P, Rosso E, Fuchshuber P, Oussoultzoglou E, De Blasi V, Simone G, Belletier C, Dufour P, Bachellier P.
    Oncology; 2015 Apr 29; 89(1):37-46. PubMed ID: 25766660
    [Abstract] [Full Text] [Related]

  • 9. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK, Byun JH, Kang JH, Son JH, Kim JH, Lee SS, Kim HJ, Yoo C, Kim KP, Hong SM, Seo DW, Kim SC, Lee MG.
    Eur Radiol; 2021 Feb 29; 31(2):813-823. PubMed ID: 32845389
    [Abstract] [Full Text] [Related]

  • 10. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ.
    Am J Clin Oncol; 2016 Feb 29; 39(1):1-7. PubMed ID: 26132367
    [Abstract] [Full Text] [Related]

  • 11. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM, Wo JY, Ferrone CR, Horick NK, Keane FK, Qadan M, Lillemoe KD, Hong TS, Clark JW, Blaszkowsky LS, Allen JN, Castillo CF.
    Ann Surg Oncol; 2020 May 29; 27(5):1400-1406. PubMed ID: 31758284
    [Abstract] [Full Text] [Related]

  • 12. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J.
    Ann Surg Oncol; 2015 Dec 29; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [Abstract] [Full Text] [Related]

  • 13. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
    Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E, Alliance for Clinical Trials on Oncology.
    BMC Cancer; 2017 Jul 27; 17(1):505. PubMed ID: 28750659
    [Abstract] [Full Text] [Related]

  • 14. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
    Schneitler S, Kröpil P, Riemer J, Antoch G, Knoefel WT, Häussinger D, Graf D.
    World J Gastroenterol; 2015 May 28; 21(20):6384-90. PubMed ID: 26034375
    [Abstract] [Full Text] [Related]

  • 15. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH.
    J Surg Oncol; 2016 Oct 28; 114(5):587-596. PubMed ID: 27444658
    [Abstract] [Full Text] [Related]

  • 16. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
    Pietrasz D, Marthey L, Wagner M, Blanc JF, Laurent C, Turrini O, Raoul JL, Terrebonne E, Hentic O, Trouilloud I, Coriat R, Regenet N, Innominato P, Taieb J, Cunha AS, Bachet JB.
    Ann Surg Oncol; 2015 Dec 28; 22 Suppl 3():S1196-205. PubMed ID: 26271395
    [Abstract] [Full Text] [Related]

  • 17. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP.
    JAMA Surg; 2016 Aug 17; 151(8):e161137. PubMed ID: 27275632
    [Abstract] [Full Text] [Related]

  • 18. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A, Lahat G, Geva R, Nachmany I, Nakache R, Goykhman Y, Brazowski E, Rosen G, Isakov O, Wolf I, Klausner JM, Lubezky N.
    Eur J Surg Oncol; 2018 Oct 17; 44(10):1619-1623. PubMed ID: 30146251
    [Abstract] [Full Text] [Related]

  • 19. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
    Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS.
    Oncologist; 2013 Oct 17; 18(5):543-8. PubMed ID: 23657686
    [Abstract] [Full Text] [Related]

  • 20. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH, Lee SS, Kim JH, Byun JH, Kim HJ, Yoo C, Kim KP, Ryoo BY, Kim SC.
    Eur Radiol; 2021 Feb 17; 31(2):864-874. PubMed ID: 32813104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.